Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCR-ABL1 E255K
i
Other names:
BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
25
;
613
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
dasatinib
Sensitive: B - Late Trials
dasatinib
Sensitive
:
B
dasatinib
Sensitive: B - Late Trials
dasatinib
Sensitive
:
B
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
bosutinib
Resistant: C3 – Early Trials
bosutinib
Resistant
:
C3
bosutinib
Resistant: C3 – Early Trials
bosutinib
Resistant
:
C3
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
imatinib
Resistant: C3 – Early Trials
imatinib
Resistant
:
C3
imatinib
Resistant: C3 – Early Trials
imatinib
Resistant
:
C3
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
BCR-ABL1 E255K
B Acute Lymphoblastic Leukemia
BCR-ABL1 E255K
B Acute Lymphoblastic Leukemia
S81694
Sensitive: D – Preclinical
S81694
Sensitive
:
D
S81694
Sensitive: D – Preclinical
S81694
Sensitive
:
D
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
CUDC-907
Sensitive: D – Preclinical
CUDC-907
Sensitive
:
D
CUDC-907
Sensitive: D – Preclinical
CUDC-907
Sensitive
:
D
BCR-ABL1 E255K
Chronic Myeloid Leukemia
BCR-ABL1 E255K
Chronic Myeloid Leukemia
dasatinib + imatinib
Resistant: D – Preclinical
dasatinib + imatinib
Resistant
:
D
dasatinib + imatinib
Resistant: D – Preclinical
dasatinib + imatinib
Resistant
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.